Summary of Findings Comparing MI, No MI in Adolescents With Overweight or Obesity
| Outcomes . | Follow-up mo . | Participants (Studies) . | Quality of Evidence (GRADE) . | I2 Statistic . | Reasons for Downgradinga,b . | Effect Estimatec MD (95% CI) . |
|---|---|---|---|---|---|---|
| BMI | 3–13 | 1185 (10 RCTs) | ⊕⊕⊕⊝ | 31% (P = .16) | Imprecision | −0.27 (−0.98 to 0.44) |
| Moderate | ||||||
| BMI percentile | 4–7 | 72 (2 RCTs) | ⊕⊕⊕⊝ | 0% (P = .46) | Imprecision | −1.07% (−3.63 to 1.48) |
| Moderate | ||||||
| BMI z score | 4–13 | 628 (6 RCTs) | ⊕⊕⊕⊝ | 47% (P = .09) | Imprecision | −0.00 (−0.09 to 0.09) |
| Moderate | ||||||
| Waist circumference | 4–13 | 633 (7 RCTs) | ⊕⊕⊕⊝ | 0% (P = .45) | Imprecision | 0.56 cm (−1.07 to 2.19) |
| Moderate | ||||||
| Glucose (fasting) | 6–13 | 290 (3 RCTs) | ⊕⊕⊕⊝ | 17% (P = .30) | Imprecision | 0.11 mmol/L (0.01 to 0.21) |
| Moderate | ||||||
| Triglycerides (fasting) | 7–13 | 401 (3 RCTs) | ⊕⊕⊝⊝ | 77% (P = .01) | Imprecision, Inconsistency | 0.00 mmol/L (−0.31 to 0.31) |
| Low | ||||||
| Total cholesterol (fasting) | 6–12 | 356 (2 RCTs) | ⊕⊕⊕⊝ | 0% (P = .39) | Imprecision | 0.01 mmol/L (−0.17 to 0.18) |
| Moderate | ||||||
| Insulin (fasting) | 6–13 | 291 (3 RCTs) | ⊕⊕⊕⊝ | 18% (P = .30) | Imprecision | 5.24 pmol/L (−13.63 to 24.10) |
| Moderate |
| Outcomes . | Follow-up mo . | Participants (Studies) . | Quality of Evidence (GRADE) . | I2 Statistic . | Reasons for Downgradinga,b . | Effect Estimatec MD (95% CI) . |
|---|---|---|---|---|---|---|
| BMI | 3–13 | 1185 (10 RCTs) | ⊕⊕⊕⊝ | 31% (P = .16) | Imprecision | −0.27 (−0.98 to 0.44) |
| Moderate | ||||||
| BMI percentile | 4–7 | 72 (2 RCTs) | ⊕⊕⊕⊝ | 0% (P = .46) | Imprecision | −1.07% (−3.63 to 1.48) |
| Moderate | ||||||
| BMI z score | 4–13 | 628 (6 RCTs) | ⊕⊕⊕⊝ | 47% (P = .09) | Imprecision | −0.00 (−0.09 to 0.09) |
| Moderate | ||||||
| Waist circumference | 4–13 | 633 (7 RCTs) | ⊕⊕⊕⊝ | 0% (P = .45) | Imprecision | 0.56 cm (−1.07 to 2.19) |
| Moderate | ||||||
| Glucose (fasting) | 6–13 | 290 (3 RCTs) | ⊕⊕⊕⊝ | 17% (P = .30) | Imprecision | 0.11 mmol/L (0.01 to 0.21) |
| Moderate | ||||||
| Triglycerides (fasting) | 7–13 | 401 (3 RCTs) | ⊕⊕⊝⊝ | 77% (P = .01) | Imprecision, Inconsistency | 0.00 mmol/L (−0.31 to 0.31) |
| Low | ||||||
| Total cholesterol (fasting) | 6–12 | 356 (2 RCTs) | ⊕⊕⊕⊝ | 0% (P = .39) | Imprecision | 0.01 mmol/L (−0.17 to 0.18) |
| Moderate | ||||||
| Insulin (fasting) | 6–13 | 291 (3 RCTs) | ⊕⊕⊕⊝ | 18% (P = .30) | Imprecision | 5.24 pmol/L (−13.63 to 24.10) |
| Moderate |
High risk of bias due to lack of blinding; less crucial in objective outcome measurements. Potential limitations unlikely lower the confidence in estimate of effect. No serious limitation; do not downgrade.
Participant age range included adolescent populations. When mean participant age was <12 y, authors were contacted for direct adolescent specific data. Greater percentage of girls than boys overall. No serious limitation; do not downgrade.
Inverse-variance statistical method using a fixed or random (when I2 >50%) effects analysis model with an MD effect measure produced by RevMan.